Bortezomib has little ex vivo activity in chronic myeloid leukemia: individual tumor response testing comparative study in acute and chronic myeloid leukemia

AIM OF THE STUDY: Resistance to imatinib is one of the most important issues in treatment of chronic myeloid leukemia (CML) patients. The objective of the study was to analyze the ex vivo drug resistance profile to bortezomib and 22 other antileukemic drugs, including three tyrosine kinase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Styczyński, Jan, Gil, Lidia, Czyżewski, Krzysztof, Kołodziej, Beata, Kuryło-Rafińska, Beata, Lewandowski, Krzysztof, Gniot, Michał, Lewandowska, Maria, Komarnicki, Mieczysław, Wysocki, Mariusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2012
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687416/
https://www.ncbi.nlm.nih.gov/pubmed/23788881
http://dx.doi.org/10.5114/wo.2012.29286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687416/
https://www.ncbi.nlm.nih.gov/pubmed/23788881
http://dx.doi.org/10.5114/wo.2012.29286

Ejemplares similares